| BACKG ROU N D
Congenital deficiencies of clotting factor VIII (haemophilia A) or factor IX (haemophilia B) cause repeated joint bleeding and crippling arthropathy. Lifelong replacement of the missing protein by repeated intravenous infusion (prophylaxis) has been shown effective to slow the process, 1 and the recent introduction of longer acting engineered factor concentrates or mimetics 2 has increased the feasibility and acceptability of treatment, including for patients with inhibitory antibodies. Cost, along with the demands of full adherence to prophylaxis, remains barriers to treatment availability and/ or sustainability, 3 depending on the setting and particularly when replacement aims to raise factor to levels enabling enjoyment of a fully active life. 4 The treatment of patients with gene constructs capable of restoring the sustained production of the (previously) deficient factor to normal or quasi-normal level has been achieved in several gene therapy trials. [5] [6] [7] Gene therapy has the potential to repair the defect causing haemophilia, overcoming all limitations of the existing treatment approaches and dramatically impacting quality of life.
Improving the health of a patient population by introducing new treatments (modalities) requires covering all the steps in the progression from discovery to market availability, through regulatory approval, health technology assessment and market access decisions (including coverage and reimbursement). Even for conventional treatments, this can take years, considering the composite body of evidence required.
Evidence generation in congenital, chronic rare diseases is further complicated by the paucity of patients, the time needed to develop and validate outcome instruments and other ethical and practical barriers to perform clinical research. 8 Among the avoidable barriers to generate robust and sufficient bodies of evidence is ensuring that outcomes selected for clinical trials are harmonized across studies, thereby allowing maximal post-trial appraisal and decisional processes by trusted pooled analyses and indirect comparisons. 9 The Core Outcome Measures in Effectiveness Trials (COMET) Initiative has shown the value of agreeing on core outcome sets.
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With haemophilia gene therapy strategies moving into advanced clinical testing, there is urgent need to identify and agree upon a core set of outcomes covering the essential needs of regulatory approval, health technology assessment and market access. Measuring similar outcomes across all forthcoming trials will maximize collective research results and patient communities' efforts, and facilitate appropriate decisions by health policy makers.
| Aim of the study
The aim of the study is to determine a core set of outcomes required to evaluate efficacy, safety, comparative effectiveness and value of gene therapy for haemophilia and rapidly disseminate the resulting core outcome set for incorporation in forthcoming clinical trials. A literature review and key informant interviews were used to create an initial list of outcomes, organized based on the COMET naming schematic for domains. A rating scale from 1 (not important to include in the core set) to 9 (essential to include) was used. Participants could suggest new outcomes to include or recover after deletion.
| MATERIAL AND ME THODS
Outcomes were eliminated if <70% of voters rated the outcome from 7 to 9, but reproposed for vote if the patient stakeholder group average score was 7 or higher (a mechanism implemented to ensure that the patient voice was not overcome), requiring a revote after additional discussion. (Table 1) .
| RE SULTS

| D ISCUSS I ON
coreHEM convened a multidisciplinary panel of patients, clinicians, researchers, drug developers, methodologists, regulators, health technology assessors and payers, who agreed upon a core set of outcomes for haemophilia gene therapy trials. To the best of our knowledge, this is the first time that a core outcome set has been created with the explicit objective of supporting all steps in the life cycle of drug development from clinical development through to market access.
coreHEM has been an innovative process. All participants are experienced experts in their own field, yet most acknowledged the value and richness of the conversation and thought process which informed the consensus process. None of them reported a similar previous experience, which may partly explain the >90% participation rate in all steps of the project.
coreHEM's generated core outcome set is innovative. Of the six core outcomes, only frequency of bleeds is a "legacy" outcome, consistently used in past haemophilia trials; its inclusion in the core will enable comparing efficacy and effectiveness with existing treatment and also calculating derived measures such as impact on target joints, a surrogate endpoint for long-term joint function deterioration. Achieved factor activity level (i.e restoration of lacking clotting capacity) was the single measure required for approval in the early era of haemophilia treatment, but was later eclipsed by outcomes geared to show the clinical impact of achieving minimal factor activity levels with prophylactic treatment. With gene therapy achieving near-normal factor activity levels, measurement of factor levels is being actively discussed Second, one might argue a core set would better serve a disease than a treatment and therefore be more impactful if built to allow comparison of all available treatments. We in principle agree, and indeed we believe, coreHEM could be fruitfully adopted for other novel treatments in the field, as is or with minor modification which we will consider in future phases of the project.
The ultimate value of the coreHEM core outcome set will be demonstrated by its uptake and efficiency in generating relevant bodies of evidence. The likelihood for success is supported by other core outcome sets which dramatically changed the course of management and treatment of the diseases for which they were 
Duration of expression
Physiological/clinical How long after the gene therapy treatment the expression of FVIII or FIX lasts; the length of time that the heightened factor activity level is maintained.
Chronic pain Pain/discomfort The presence of persistent pain that can last for a long time, such as over months or longer, including the frequency, intensity, duration and character of the pain.
Utilization of healthcare system (direct costs)
Resource use Measures of uses and related costs incurred from the need for health care and treatment associated with haemophilia, including days in hospital, hospital readmissions, emergency room visits, bleeds, inhibitors, factor VIII/IX infusion, bypass agent use, pain and other medications, home health/homecare services, specialist consultations and professional caregivers.
Mental health Emotional functioning A person's psychological status; whether a person has positive feelings (joy, excitement, ease of living, new outlook on life) or negative feelings (anxiety, depression, fear, uncertainty) associated with having haemophilia or the treatment of haemophilia. Can be related to the act of making an irreversible treatment decision or the effect of the gene therapy in curing one's haemophilia.
Important adverse events
Liver toxicity Short-term adverse events Measured by elevated levels of liver enzymes in the blood (a possible response to the gene therapy targeted at the liver cells, as the liver is where clotting factor is produced).
Short-term immune response to FVIII/ FIX (inhibitor development)
Short-term adverse events After the gene for the missing clotting factor (FVIII or FIX) is inserted into the cell and starts producing the missing protein, the body may initiate an immune response (inhibitors) against FVIII or FIX (patients with inhibitors may stop responding to factor VIII and IX and require special and expensive treatments for bleeds).
Immune response to gene therapy (cytotoxic)
Short-term adverse events When gene therapy is administered, the patient's body may mount an immune response against elements of the product injected (antibodies against the viral vector, gene therapy vector capsidspecific T cells, etc.).
Thrombosis
Short-term adverse events The formation of a blood clot, which can obstruct the flow in a blood vessel.
Development of other disorders
Long-term adverse events Development of serious medical problems associated with gene therapy such as cancer.
Vector integration into host genome
Long-term adverse events An adverse form of vector integration such as the DNA of the virus vector used to deliver the gene therapy to the cells becomes integrated into the human cells, potentially altering the expression, and potentially the function, of the genes or causing other genes to become inactivated.
Duration of vector-neutralizing response
Long-term adverse events The length of time a patient's body maintains an immune response to the viral vector. Gene therapy uses a viral vector to deliver the necessary clotting factor DNA to the cells. The body develops an immune response against the viral vector, therefore preventing any readministration of gene therapy using the same viral vector.
Cause of death Mortality The determination of the reason for a patient's death.
The table reports the final set of outcomes identified in the process. Top half: efficacy and effectiveness outcomes; bottom half: safety outcomes.
forthcoming clinical trials. Regulators, health technology assessors and payers are likely to recognize the results generated in the trials using the coreHEM core set, given their active involvement in selecting the core outcomes.
coreHEM will need to be complemented with selecting the appropriate measures for some of the identified outcomes. This process is underway, primed by focused discussion within the consensus group. Providing a full framework to bridge the outcome set to a fully fledged value-based approach 14 will also be a goal of subsequent coreHEM research. 
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